Portal de Periódicos da CAPES

Carvedilol in Dogs with Dilated Cardiomyopathy

2007; Wiley; Volume: 21; Issue: 6 Linguagem: Inglês

10.1892/07-034.1

1939-1676

Mark A. Oyama, D. David Sisson, Robert A. Prosek, Barret J. Bulmer, Mike W. Luethy, Virginia Luis Fuentes,

Cardiovascular Function and Risk Factors

Journal of Veterinary Internal MedicineVolume 21, Issue 6 p. 1272-1279 Open Access Carvedilol in Dogs with Dilated Cardiomyopathy Mark A. Oyama, Corresponding Author Mark A. Oyama Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL Dr Oyama is presently affiliated with the Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA. DVM, DACVIM-Cardiology, Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104; e-mail: maoyama@vet.upenn.edu.Search for more papers by this authorD. David Sisson, D. David Sisson Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL Dr Sisson and Dr Bulmer are presently affiliated with the Department of Clinical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR.Search for more papers by this authorRobert Prošek, Robert Prošek Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL Dr Prošek is presently affiliated with Veterinary Specialists Inc, Homestead, FL.Search for more papers by this authorBarret J. Bulmer, Barret J. Bulmer Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL Dr Sisson and Dr Bulmer are presently affiliated with the Department of Clinical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR.Search for more papers by this authorMike W. Luethy, Mike W. Luethy Animal Emergency & Critical Care Center, Northbrook, ILSearch for more papers by this authorVirginia Luis Fuentes, Virginia Luis Fuentes Department of Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus OH Dr Luis Fuentes is presently affiliated with the Department of Clinical Studies, Royal Veterinary College, Hatfield, UK.Search for more papers by this author Mark A. Oyama, Corresponding Author Mark A. Oyama Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL Dr Oyama is presently affiliated with the Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA. DVM, DACVIM-Cardiology, Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104; e-mail: maoyama@vet.upenn.edu.Search for more papers by this authorD. David Sisson, D. David Sisson Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL Dr Sisson and Dr Bulmer are presently affiliated with the Department of Clinical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR.Search for more papers by this authorRobert Prošek, Robert Prošek Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL Dr Prošek is presently affiliated with Veterinary Specialists Inc, Homestead, FL.Search for more papers by this authorBarret J. Bulmer, Barret J. Bulmer Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL Dr Sisson and Dr Bulmer are presently affiliated with the Department of Clinical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR.Search for more papers by this authorMike W. Luethy, Mike W. Luethy Animal Emergency & Critical Care Center, Northbrook, ILSearch for more papers by this authorVirginia Luis Fuentes, Virginia Luis Fuentes Department of Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus OH Dr Luis Fuentes is presently affiliated with the Department of Clinical Studies, Royal Veterinary College, Hatfield, UK.Search for more papers by this author First published: 28 June 2008 https://doi.org/10.1111/j.1939-1676.2007.tb01949.xCitations: 10 AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Background: Dilated cardiomyopathy (DCM) is characterized by reduced systolic function, heightened sympathetic tone, and high morbidity and mortality. Little is known regarding the safety and efficacy of ß-blocker treatment in dogs with DCM. Hypothesis: Carvedilol improves echocardiographic and neurohormonal variables in dogs with DCM over a 4-month treatment period. Methods: Prospective, placebo-controlled, double-blinded randomized study. Dogs with DCM underwent echocardiography, ECG, thoracic radiographs, and neurohormonal profiling, followed by titration onto Carvedilol (0.3 mg/kg q12h) or placebo over a 4-week period and subsequently received 3 months of therapy. Primary study endpoints included left ventricular volume and function. Results: Sixteen dogs received carvedilol and 7 received placebo. At study end, 13 carvedilol dogs and 5 placebo dogs were alive. There was no difference in the mean percentage change in left ventricular volume at end-diastole (LVVd), left ventricular end-systolic volume (LVVs), and ejection fraction (EF) between treatment groups, suggesting that both groups experienced similar amounts of disease progression. Carvedilol treatment did not result in significant changes in neurohormonal activation, radiographic heart size, heart rate, or owner perceived quality-of-life. Baseline B-type natriuretic peptide (BNP) predicted dogs in the carvedilol-treated group that maintained or improved their EF over the study duration. Conclusions and Clinical Importance: Carvedilol administration did not improve echocardiographic or neurohormonal indicators of heart function. The lack of effect may be related to severity of disease, carvedilol dose, or brevity of follow-up time. Statistical power of the present study was adversely affected by a high fatality rate in study dogs and small sample size. Citing Literature Volume21, Issue6November 2007Pages 1272-1279 ReferencesRelatedInformation